Get started
Author

Xiuman Zhou

Blocking of the PD‐1/PD‐L1 Interaction by a D ‐Peptide Antagonist for Cancer Immunotherapy
2015 · Hao‐Nan Chang, Bei‐Yuan Liu, et al. · Angewandte Chemie International Edition · 398
A Novel d ‐Peptide Identified by Mirror‐Image Phage Display Blocks TIGIT/PVR for Cancer Immunotherapy
2020 · Xiuman Zhou, Chao Zuo, et al. · Angewandte Chemie International Edition · 167
CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy
2020 · Hongfei Wang, Yixuan Sun, et al. · Journal for ImmunoTherapy of Cancer · 123
PDF
Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells
2018 · Xiu-Man Zhou, Wan-Qiong Li, et al. · Frontiers in Immunology · 114
PDF
Engineered Nanovaccine Targeting Clec9a + Dendritic Cells Remarkably Enhances the Cancer Immunotherapy Effects of STING Agonist
2021 · Shanshan Gou, Wenwen Liu, et al. · Nano Letters · 100
An orally available PD-1/PD-L1 blocking peptide OPBP-1-loaded trimethyl chitosan hydrogel for cancer immunotherapy
2021 · Wanqiong Li, Xueqin Zhu, et al. · Journal of Controlled Release · 94
A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses
2020 · Wenjie Zhai, Xiuman Zhou, et al. · Acta Pharmaceutica Sinica B · 92
PDF
Chemotherapy-induced apoptosis in melanoma cells is p53 dependent
1998 · G Li, L Tang, et al. · Melanoma Research · 91
A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy
2025 · Youmei Xiao, Zhuoying He, et al. · Nature Communications · 90
PDF
Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy
2023 · Wenhui Shen, Peishang Shi, et al. · Journal for ImmunoTherapy of Cancer · 73
PDF
A novel peptide targeting Clec9a on dendritic cell for cancer immunotherapy
2016 · Zhongyi Yan, Yahong Wu, et al. · Oncotarget · 64
PDF
Tryptophan 2,3-dioxygenase 2 controls M2 macrophages polarization to promote esophageal squamous cell carcinoma progression via AKT/GSK3β/IL-8 signaling pathway
2021 · Yumiao Zhao, Jiaxin Sun, et al. · Acta Pharmaceutica Sinica B · 60
PDF
Characterization of CD103+ CD8+ tissue-resident T cells in esophageal squamous cell carcinoma: may be tumor reactive and resurrected by anti-PD-1 blockade
2020 · Lu Han, Quan-Li Gao, et al. · Cancer Immunology Immunotherapy · 59
Dual Blockade of Lactate/GPR81 and PD-1/PD-L1 Pathways Enhances the Anti-Tumor Effects of Metformin
2021 · Shaomeng Chen, Xiuman Zhou, et al. · Biomolecules · 57
PDF
Rational Design of Potent Peptide Inhibitors of the PD-1:PD-L1 Interaction for Cancer Immunotherapy
2021 · Huawu Yin, Xiuman Zhou, et al. · Journal of the American Chemical Society · 55
Extracellular vesicle IL-32 promotes the M2 macrophage polarization and metastasis of esophageal squamous cell carcinoma via FAK/STAT3 pathway
2022 · Yixuan Sun, Yuzhen Qian, et al. · Journal of Experimental & Clinical Cancer Research · 52
PDF
Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy
2020 · Wenjie Zhai, Xiuman Zhou, et al. · Science China Life Sciences · 51
Identification of a novel DEC-205 binding peptide to develop dendritic cell-targeting nanovaccine for cancer immunotherapy
2024 · Jie Zheng, Mingshuang Wang, et al. · Journal of Controlled Release · 49
Fish oil-based microemulsion can efficiently deliver oral peptide blocking PD-1/PD-L1 and simultaneously induce ferroptosis for cancer immunotherapy
2023 · Xin Yang, Wanqiong Li, et al. · Journal of Controlled Release · 37
Integrative analysis of bulk and single-cell gene expression profiles to identify tumor-associated macrophage-derived CCL18 as a therapeutic target of esophageal squamous cell carcinoma
2023 · Xinghua Sui, Chunxia Chen, et al. · Journal of Experimental & Clinical Cancer Research · 37
PDF
A PD-L1 and VEGFR2 dual targeted peptide and its combination with irradiation for cancer immunotherapy
2022 · Ling Jiao, Qingyu Dong, et al. · Pharmacological Research · 37
Design of a novel chimeric peptide via dual blockade of CD47/SIRPα and PD-1/PD-L1 for cancer immunotherapy
2023 · Zheng Hu, Wanqiong Li, et al. · Science China Life Sciences · 36
Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy
2023 · Yuzhen Qian, Yixuan Sun, et al. · Acta Pharmaceutica Sinica B · 34
Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy
2021 · Xiuman Zhou, Ling Jiao, et al. · Biomolecules · 34
PDF
Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR
2020 · Xiuman Zhou, Jiangfeng Du, et al. · Cell Communication and Signaling · 33
PDF
Works count: 68
Citation count: 2,425
H-index: 27
I10-index: 40
Year
Topic
Type